Fulcrum Therapeutics, Inc. Net Income Loss

• Fulcrum Therapeutics, Inc. showed a decrease of -670.0% in Net Income Loss from 2024 to 2025.
• This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Net Income Loss has declined by 129.8%.
• Historical annual values: Fiscal year 2025: -$74.88 million | Fiscal year 2024: -$9.73 million | Fiscal year 2023: -$97.34 million | Fiscal year 2022: -$109.87 million | Fiscal year 2021: -$80.85 million | Fiscal year 2020: -$70.82 million | Fiscal year 2019: -$82.68 million | Fiscal year 2018: -$32.59 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026